Advesya is a pioneering biopharma company for difficult-to-treat cancers.
The creation of Advesya was based on decades of research carried out by experienced scientists from the French Blood Institute (EFS) who spun off the activity in 2021.
Advesya aims to rapidly bring new innovations to the cancer therapy sector, starting with aiding refractory Acute Myeloid Leukemia patients, followed by other hematological malignancies.